B-Type Natriuretic Peptide in Aortic Stenosis New Insight in the Era of Biomarkers?∗ by Seferovic, Petar M.
Journal of the American College of Cardiology Vol. 63, No. 19, 2014
 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2014.02.579EDITORIAL COMMENTB-Type Natriuretic
Peptide in Aortic Stenosis
New Insight in the Era of Biomarkers?*
Petar M. Seferovic, MD, PHD
Belgrade, Serbia*Editorials p
views of th
American C
From the
icine and He
Dr. Seferovi
paper to dis“...little things are inﬁnitely the most important”
dSir Arthur Conan Doyle (1859–1930) (1)
B-type natriuretic peptide (BNP) has been described as a
potential indicator of disease severity in aortic stenosis
(AS). BNP is released predominantly in the left ventricle
(LV), and its level correlates with aortic valve area (AVA),
transvalvular gradient, patient functional status, LV dia-
stolic dysfunction, and LV end-systolic wall stress in AS
(2–4). Both LV dysfunction and levels of BNP were shown
to have prognostic value in asymptomatic AS, deﬁned as a
group of particular clinical interest (2). Repeated measure-
ments of plasma BNP can give additional value to clinical
and echocardiographic assessment in post-operative follow-
up in asymptomatic patients with AS after aortic valve
replacement (AVR) (5). However, in contrast to heart
failure, biomarkers have not been used in the assessment
of diagnostic or prognostic aspects of valvular heart
disease (6).See page 2016In this issue of the Journal, Clavel et al. (7) report on a
prospective observational study in a large number of patients
with AS. All patients had clinical evaluation and Doppler
echocardiographic assessment simultaneously with BNP
measurement. The study has several methodological advan-
tages, including large sample size (n ¼ 1,953), appropriately
applied exclusion criteria, high event rate, and hard endpoint.
In addition, follow-up time was long (up to 8 years) and
time-dependent analysis was used to determine the outcome
of AVR.
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c has reported that he has no relationships relevant to the contents of this
close.activation, which allowed overcoming the obstacle of
different BNP normal ranges related to age, sex, and various
assays, thus individualizing BNP values to each patient (7).
BNP level has been previously conﬁrmed as an inde-
pendent predictor of mortality in patients with AS, but
these ﬁndings originated from small samples observed in
short follow-up periods (4,8). In this study, elevated BNP
level was associated with poor prognosis in AS, suggesting
that BNP clinical activation independently correlated with
long-term survival and should be used as an important
parameter in indicating AVR (7). However, the critical view
that BNP clinical activation may not be caused by only AS
but also by other comorbidities may be correct and should
be proved by large clinical trials. Adding BNP clinical
activation to other standard parameters used for considering
surgery is strengthened by crucial new facts presented in the
paper. BNP was nearly independent of AVA (r ¼ 0.10;
p < 0.001) and mean gradient (r ¼ 0.12; p < 0.0001) and,
in multivariate analysis, was predictive for all measures of
AS severity and consequences. This is supported by the fact
that in isolated AS, BNP was proved as a major indepen-
dent determinant of survival after diagnosis and was a useful
predictor of the clinical beneﬁt of AVR.
The degree of BNP clinical activation was also associated
with mortality in speciﬁc group of asymptomatic patients
with severe AS, with an adjusted hazard ratio of 7.38 if the
BNP ratio was 3 (7). Because early AVR in asymptomatic
severe AS is controversial, considering the risk of sudden
death and progressive LV dysfunction, this fact adds an
important clinical aspect to the body of previous knowledge
(4,9). Therefore, BNP may be useful as a noninvasive and
reproducible tool in screening asymptomatic patients who
will beneﬁt from surgery.
The study has the following limitations.
Serial BNP measurements in this study were not per-
formed, and therefore, BNP dynamicity was not followed.
Bergler-Klein et al. (3) suggested that serial measurements
of BNP are important and may contribute to adequate
referral of asymptomatic patients with AS to valve surgery,
whereas onset of symptoms indicates short survival. Also,
elevated natriuretic peptide levels were predictors for
symptom-free survival in AS, and serial plasma levels indi-
cated symptom development and AVR (3).
Survival of the group with asymptomatic severe AS was
not separately analyzed regarding treatment. Because
hemodynamic parameters are not the best approach to
indicate surgery in this group of patients, due to variable
adaptation of the LV to pressure overload (4), BNP clinical
activation may be a useful additional guide.
The role of BNP in patients with AS may be especially
useful in speciﬁc subgroups of patients, such as those with
low-gradient “severe”AS (AVA<1 cm2; mean gradient<40
mm Hg) and preserved LV systolic function. These patients
represent a subset of approximately 30% of asymptomatic
patients with AS, with outcomes comparable to those of
moderate AS, and AVR is suggested only in symptomatic
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2027patients (10). Because these facts are based on retrospective
analysis without comparison with severe AS, prospective
analysis in the future, including BNP measurements, may be
a useful option (9,10).
Assessment of patients with AS include both clinical
approaches and precise echocardiography measurements
(9,11). Integration of BNP measurements into AS man-
agement algorithms may have potential advantages in
determining survival and indicating surgery in these patients.
BNP-guided clinical approaches, based on time-dependent
analysis revealing mortality reduction in patients with
elevated BNP levels after AVR, may be additionally helpful
in decision making for surgical consideration in AS (7). The
predictive role of BNP in clinical practice and for consid-
eration of AVR may be promising, but further studies with
better risk stratiﬁcation of patients with AS are needed to
get the ﬁnal answer.
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